Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Tours – page 41

539 clinical trials in Tours, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Tours at a glance
539
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

539 trials in Tours

Open in trial search

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Diffuse large B-cell lymphoma refractory

Not recruiting

Study on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study on Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed, Refractory, or Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Prostate cancer

Not recruiting

Study on Stereotactic Body Radiation Therapy with or without Durvalumab for Patients with Oligometastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut De Cancerologie De L Ouest

Non-small cell lung cancer

Not recruiting

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Diffuse large B-cell lymphoma+2

Not recruiting

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Squamous cell carcinoma of the hypopharynx+1

Not recruiting

Study on Preserving the Voice Box in Patients with Advanced Laryngeal or Hypopharyngeal Cancer Using Cisplatin, Fluorouracil, and Docetaxel Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Phenylketonuria

Not recruiting

Study to Evaluate mRNA-3210 for Safety and Tolerability in Patients with Phenylketonuria

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Moderna Inc.

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Tours

What the registry says about research in the country

01 Respiratory Research

Clinical trials focusing on pulmonary disorders include studies on idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, evaluating new therapeutic approaches to improve lung function and patient outcomes.

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
02 Oncology Studies

Groundbreaking research in cancer treatment encompasses multiple myeloma, leukemia, and esophageal cancer, with trials evaluating novel targeted therapies and immunotherapy approaches.

  • Multiple Myeloma
  • Acute Myeloid Leukemia
  • Colorectal Cancer
  • Pleural Mesothelioma
03 Immunology and Infectious Diseases

Research initiatives exploring immune system disorders and viral infections, including innovative vaccine development for COVID-19 and cytomegalovirus, plus studies on immunosuppression management.

  • COVID-19 Vaccines
  • Cytomegalovirus Prevention
  • Sustained Immunosuppression
04 Neurological Disorders

Studies addressing neurological conditions, focusing on multiple sclerosis treatment strategies and investigating therapies for ADHD and Alzheimer's-related psychosis.

  • Multiple Sclerosis
  • ADHD
  • Alzheimer's Disease Psychosis
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.